TIME and data firm Statista have released their annual ranking of America’s top manufacturers for 2027, assessing companies with at least $100 million in 2025 revenue and U.S. production facilities. The evaluation criteria included revenue growth from 2023 to 2025, research and development expenditure, and workforce metrics such as retention and safety records derived from public filings and government databases.
The latest list highlights a mixed picture for the U.S. manufacturing sector. While President Trump’s global tariffs were intended to repatriate production, a report by the Cato Institute indicated that a factory-building boom has not materialized, with growth largely confined to industries facing lower tariffs, such as electronics. Consequently, manufacturing jobs have not expanded as predicted; in fact, the Center for American Progress noted that approximately 89,000 manufacturing jobs were lost following the announcement of tariffs in 2025. Despite these challenges, the sector remains significant, employing 12.6 million workers as of September 2026.
Among the top performers, Eli Lilly takes the first spot, becoming the first pharmaceutical company to reach a $1 trillion market valuation. This surge is attributed to high demand for its weight-loss drugs. As part of a $27 billion investment strategy, Lilly is constructing four new manufacturing facilities in the United States, which the company projects will create 13,000 construction and manufacturing jobs. Biopharma companies dominate the top ten positions, accounting for 70% of the list, while the Industrial & Electrical Equipment sector includes 64 of the ranked companies.
The divergence in narratives is further illustrated by a November 1 report from the White House, which touted a “Manufacturing Renaissance” and $380 billion in plant investments. However, critics argue that geopolitical tensions, such as the war in Iran, have increased freight costs and disrupted supply chains, making domestic production more difficult. Rachel Slade, author of *Making It in America*, contends that policies introduced during the Biden administration, such as the Build America, Buy America Act, the Inflation Reduction Act, and the CHIPS Act, have been more effective in incentivizing investment in struggling regions than recent tariffs. Slade warns that tariffs on raw materials significantly increase production costs, hindering rather than helping domestic manufacturers.
Experts note that the U.S. manufacturing landscape is not uniformly declining or thriving but lacks consistency across the industrial base. J. Christopher Love of the MIT Initiative for New Manufacturing suggests that policy should focus on equipping existing domestic manufacturers with modern technologies rather than attempting to rebuild the industry from scratch. This is particularly relevant in the electrical equipment sector, which is currently booming due to the AI-driven expansion of data centers. For instance, Generac, ranked 85th on the list, is planning a $250 million factory expansion by the end of 2027 to produce generators for data centers. Analysts at Wood Mackenzie predict that the U.S. data center electrical equipment market will grow from $20 billion in 2025 to $65 billion by 2030, representing 40% of the total U.S. electrical equipment market.
Seventy percent of the top ten is biopharma? We basically just have one huge industry winning now. Not great.
Rachel Slade has a point. Older legislation like CHIPS actually helped struggling regions better than the recent tariff chaos.
Data center power needs are exploding. Generac expanding for that market makes perfect sense, not just for medical supplies.
The 89k job loss statistic makes me skeptical about the so-called renaissance. The tariffs are clearly hurting workers, not helping.
I am surprised Eli Lilly tops the list. Is it really a manufacturer or just a pharma giant with some new plants?